Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072967 | 0.90 | HPGD (0.65) | HPGDPOLBNR3C2LMNAALDH1A1 | |
| SCHEMBL14072995 | 0.87 | HPGD (0.57) | HPGDNR3C2LMNATSHRPRMT5 | |
| SCHEMBL6415562 | 0.86 | HPGD (0.58) | HPGDPOLBKMT2ANR3C2LMNA | |
| SCHEMBL29899544 | 0.79 | CRBN (0.56) | HPGDPOLBMEN1KMT2ATSHR | |
| SCHEMBL23143477 | 0.79 | CRBN (0.56) | HPGDPOLBMEN1KMT2ATSHR | |
| SCHEMBL7349545 | 0.78 | ALDH1A1 (0.52) | POLBLMNANSD2ALDH1A1MAPT | |
| SCHEMBL11046347 | 0.78 | NR3C1 (0.62) | HPGDPOLBMEN1KMT2ATSHR | |
| SCHEMBL14072961 | 0.77 | NR3C2 (0.61) | HPGDNR3C2LMNATSHRALDH1A1 | |
| Iodide SCHEMBL11041065 | 0.77 | NR3C1 (0.61) | HPGDPOLBMEN1KMT2ATSHR | |
| SCHEMBL941445 | 0.77 | GAA (0.56) | KMT2ANR3C2LMNANSD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | HPGD 89/4885POLB 2906/4885MEN1 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.